Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.33 |
| ▸ | ERN1 | O75460 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.31 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.31 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.31 |
| ▸ | BRD4 | O60885 | 1/20 | 0.31 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.31 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.30 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.30 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.30 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.30 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.30 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31128947 | 0.75 | KMT2A (0.35) | ALDH1A1SMN1; SMN2L3MBTL1LRRK2KMT2A | |
| SCHEMBL31128861 | 0.75 | ACHE (0.41) | KDM4CMKNK1MKNK2KMT2A | |
| SCHEMBL30255686 | 0.73 | ACHE (0.36) | KDM4CLRRK2 | |
| SCHEMBL2593564 | 0.73 | — | — | |
| SCHEMBL29217192 | 0.72 | ABL1 (0.36) | L3MBTL1BRD4 | |
| Boric Acid SCHEMBL29129554 | 0.72 | EPAS1 (0.31) | — | |
| SCHEMBL31389091 | 0.71 | ROCK2 (0.40) | ALDH1A1HTT | |
| SCHEMBL31128872 | 0.71 | CHRNB2 (0.33) | ALDH1A1SMN1; SMN2L3MBTL1 | |
| SCHEMBL25880683 | 0.71 | — | — | |
| SCHEMBL15190472 | 0.71 | ABL1 (0.44) | ALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114539279-B | Oxidobicycloheptene sulfonamide compound containing five-membered nitrogen heterocycle and application thereof in preparation of anti-breast cancer drugs | 武汉大学 | 2023-02-24 | — | — | CN | claimed |
| CN-114539279-A | Oxidobicycloheptene sulfonamide compound containing five-membered nitrogen heterocycle and application thereof in preparation of anti-breast cancer drugs | 武汉大学 | 2022-05-27 | — | — | CN | claimed |
| WO-2025087295-A1 | PI3K INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 海创药业股份有限公司 | 2025-05-01 | — | — | WO | disclosed |
| CN-119330967-B | MET transcription inhibitor and preparation method and application thereof | 中国药科大学 | 2025-04-25 | — | — | CN | disclosed |
| WO-2025067509-A1 | EGFR DEGRADANT, AND PREPARATION METHOD AND USE THEREFOR | 石药集团中奇制药技术（石家庄）有限公司 | 2025-04-03 | — | — | WO | disclosed |
| CN-119654321-A | PI3K alpha inhibitors | 突触活化疗法股份有限公司 | 2025-03-18 | — | — | CN | disclosed |
| CN-119528910-A | Carboxyl condensed ring derivative regulator, preparation method and application thereof | 江苏豪森药业集团有限公司 | 2025-02-28 | — | — | CN | disclosed |
| WO-2025021148-A1 | WRN INHIBITOR, AND PHARMACEUTICAL COMPOSITION THEREOF AND USE THEREOF | 贝达药业股份有限公司 | 2025-01-30 | — | — | WO | disclosed |
| CN-119330967-A | MET transcription inhibitor and preparation method and application thereof | 中国药科大学 | 2025-01-21 | — | — | CN | disclosed |
| US-12162876-B2 | Indazole kinase inhibitor and use thereof | Tarapeutics Science Inc. (CN) | 2024-12-10 | — | — | US | disclosed |
| WO-2024245143-A1 | USE OF PHARMACEUTICAL COMPOSITION COMPRISING COMPOUND HAVING BIS(AZANYLYLIDENE) SULFONYL STRUCTURE FOR TREATING ANEMIA-RELATED DISEASES | 赛诺哈勃药业（成都）有限公司 | 2024-12-05 | — | — | WO | disclosed |
| CN-115093400-A | AhR inhibitor and application and preparation method thereof | 重庆华森制药股份有限公司 | 2022-09-23 | — | — | CN | disclosed |
| CN-114560867-A | Oxocycloheptene sulfonate compound containing five-membered nitrogen heterocycle and application thereof in preparation of anti-breast cancer drugs | 武汉大学 | 2022-05-31 | — | — | CN | disclosed |
| CN-114539279-A | Oxidobicycloheptene sulfonamide compound containing five-membered nitrogen heterocycle and application thereof in preparation of anti-breast cancer drugs | 武汉大学 | 2022-05-27 | — | — | CN | disclosed |
| US-20220002287-A1 | INDAZOLE KINASE INHIBITOR AND USE THEREOF | Tarapeutics Science Inc. (CN) | 2022-01-06 | — | — | US | disclosed |
| EP-3878841-A1 | INDAZOLE KINASE INHIBITOR AND USE THEREOF | Tarapeutics Science Inc. (CN) | 2021-09-15 | — | — | EP | disclosed |
| CN-104428293-B | Adjust the benzimidazole of TNF α | UCB生物制药私人有限公司 | 2018-06-08 | — | — | CN | disclosed |
| CN-106336413-A | Compounds used as JAK inhibitor, and use of compounds | 广东东阳光药业有限公司 | 2017-01-18 | — | — | CN | disclosed |
| US-20100113418-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-05-06 | — | — | US | disclosed |
| EP-2123652-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2009-11-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12162876-B2 | Indazole kinase inhibitor and use thereof | FLT3, PDGFRB, FLT1 | KDM4C 2268/4885ERN1 2226/4885ALDH1A1 1073/4885 |
| US-20220002287-A1 | INDAZOLE KINASE INHIBITOR AND USE THEREOF | FLT3, FGFR1, FLT1 | KDM4C 2309/4885ERN1 2142/4885ALDH1A1 1239/4885 |
| US-20100113418-A1 | HETEROCYCLIC COMPOUND | ACACA, ACAT1, CPT1B | KDM4C 971/4885ERN1 3452/4885ALDH1A1 503/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.